



ASX ANNOUNCEMENT

12 October 2010

First VitroGro® Patent Allowed in Europe

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced today that the European Patent Office (EPO) has issued a Notice to the Company stating that the EPO intends to grant the core VitroGro® patent, "Skin Regeneration System".

This means that all claims contained in this patent have been allowed by the EPO and that this patent will be granted subject to the payment of the translation and printing fee by Tissue Therapies. This payment has been made.

Dr Steven Mercer, the CEO of Tissue Therapies said, "The allowance of this core patent means that the most commercially important VitroGro® intellectual property is now protected in all major world jurisdictions."

"The allowance of this patent in the European Union represents a significant step in securing the VitroGro® intellectual property as part of the VitroGro® commercialisation process and building value in the Company."

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell-based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com